Crosstown Traffic: Lymphodepleting Chemotherapy Drives CAR T Cells

David M. Davies, John Maher*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

4 Citations (Scopus)

Abstract

CAR-engineered T cell immunotherapy has proven transformative in selected hematological malignancies. However, solid tumors largely remain impervious to these approaches. In addressing this challenge, Srivastava et al. in this issue demonstrate that oxaliplatin-based lymphodepleting chemotherapy promotes enhanced CAR T cell recruitment to lung tumors, boosting therapeutic impact in combination with anti-PD-L1.

Original languageEnglish
Pages (from-to)138-140
Number of pages3
JournalCANCER CELL
Volume39
Issue number2
DOIs
Publication statusPublished - 8 Feb 2021

Fingerprint

Dive into the research topics of 'Crosstown Traffic: Lymphodepleting Chemotherapy Drives CAR T Cells'. Together they form a unique fingerprint.

Cite this